{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:05:45Z","timestamp":1789239945849,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01211-5","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T06:38:31Z","timestamp":1755585511000},"page":"2189-2203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-0780","authenticated-orcid":false,"given":"Eileen M.","family":"Dunne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linge","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Althouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Hayford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Theilacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1211_CR1","unstructured":"GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221\u201348."},{"issue":"08","key":"1211_CR2","first-page":"85","volume":"94","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper\u2013February 2019. Wkly Epidemiol Rec. 2019;94(08):85\u2013103.","journal-title":"Wkly Epidemiol Rec"},{"key":"1211_CR3","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/INF.0000000000000076","volume":"33","author":"CG Whitney","year":"2014","unstructured":"Whitney CG, Goldblatt D, O\u2019Brien KL. Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers. Pediatr Infect Dis J. 2014;33:S172\u201381.","journal-title":"Pediatr Infect Dis J"},{"issue":"28","key":"1211_CR4","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1016\/j.vaccine.2023.05.045","volume":"41","author":"K Schley","year":"2023","unstructured":"Schley K, Borchert K, Seidel K, Jacob C, von Eiff C, Laurenz M. Did the change of the vaccination schedule effect pneumococcal conjugate vaccination compliance and adherence of premature and mature born infants in Germany? Answers from a claims database analysis. Vaccine. 2023;41(28):4081\u201391.","journal-title":"Vaccine"},{"issue":"3","key":"1211_CR5","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1093\/cid\/ciac475","volume":"76","author":"LR Grant","year":"2023","unstructured":"Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert R-R, et al. Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023;76(3):e1062\u201370.","journal-title":"Clin Infect Dis"},{"key":"1211_CR6","unstructured":"World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines, Annex 3, TRS No 977. 2013."},{"issue":"5","key":"1211_CR7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae220","volume":"11","author":"K Feemster","year":"2024","unstructured":"Feemster K, Buchwald UK, Banniettis N, Joyce JG, Velentgas P, Chapman TJ, et al. Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities. Open Forum Infect Dis. 2024;11(5): ofae220.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"1211_CR8","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/INF.0000000000004300","volume":"43","author":"P Korbal","year":"2024","unstructured":"Korbal P, Wysocki J, Jackowska T, Kline M, Tamimi N, Drozd J, et al. Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2024;43(6):587\u201395.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"1211_CR9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028435","volume":"6","author":"N Andrews","year":"2011","unstructured":"Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MPE, et al. Using the indirect cohort design to estimate the effectiveness of the seven-valent pneumococcal conjugate vaccine in England and Wales. PLoS ONE. 2011;6(12): e28435.","journal-title":"PLoS ONE"},{"issue":"32","key":"1211_CR10","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","volume":"37","author":"N Andrews","year":"2019","unstructured":"Andrews N, Kent A, Amin-Chowdhury Z, Sheppard C, Fry N, Ramsay M, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006\u20132018. Vaccine. 2019;37(32):4491\u20138.","journal-title":"Vaccine"},{"issue":"16","key":"1211_CR11","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","volume":"42","author":"KL Andrejko","year":"2024","unstructured":"Andrejko KL, Gierke R, Rowlands JV, Rosen JB, Thomas A, Landis ZQ, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study. Vaccine. 2024;42(16):3555\u201363.","journal-title":"Vaccine"},{"issue":"29","key":"1211_CR12","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","volume":"40","author":"C Savulescu","year":"2022","unstructured":"Savulescu C, Krizova P, Valentiner-Branth P, Ladhani S, Rinta-Kokko H, Levy C, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Vaccine. 2022;40(29):3963\u201374.","journal-title":"Vaccine"},{"issue":"6","key":"1211_CR13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","volume":"37","author":"M Amir-Behghadami","year":"2020","unstructured":"Amir-Behghadami M, Janati A. Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews. Emerg Med J. 2020;37(6):387.","journal-title":"Emerg Med J"},{"issue":"4","key":"1211_CR14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0377","volume":"145","author":"M Berman-Rosa","year":"2020","unstructured":"Berman-Rosa M, O\u2019Donnell S, Barker M, Quach C. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4): e20190377.","journal-title":"Pediatrics"},{"key":"1211_CR15","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0000000000000078","volume":"33","author":"L Conklin","year":"2014","unstructured":"Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, et al. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J. 2014;33:S109\u201318.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"1211_CR16","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1080\/21645515.2019.1612667","volume":"15","author":"A McGirr","year":"2019","unstructured":"McGirr A, Iqbal SM, Izurieta P, Talarico C, Luijken J, Redig J, et al. A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines. Hum Vacc Immunother. 2019;15(11):2713\u201324.","journal-title":"Hum Vacc Immunother"},{"key":"1211_CR17","unstructured":"Wells G SB, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"1211_CR18","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2024. https:\/\/www.R-project.org\/."},{"issue":"3","key":"1211_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor Package. J Stat Softw. 2010;36(3):1\u201348.","journal-title":"J Stat Softw"},{"issue":"1","key":"1211_CR20","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12630","volume":"19","author":"L Olarte","year":"2017","unstructured":"Olarte L, Lin PL, Barson WJ, Romero JR, Tan TQ, Givner LB, et al. Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. Transpl Infect Dis. 2017;19(1): e12630.","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"1211_CR21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/cid\/ciu431","volume":"59","author":"C Cohen","year":"2014","unstructured":"Cohen C, von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan V, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case\u2013control study. Clin Infect Dis. 2014;59(6):808\u201318.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1211_CR22","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2214-109X(17)30043-8","volume":"5","author":"C Cohen","year":"2017","unstructured":"Cohen C, von Mollendorf C, de Gouveia L, Lengana S, Meiring S, Quan V, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case\u2013control study. Lancet Glob Health. 2017;5(3):e359\u201369.","journal-title":"Lancet Glob Health"},{"issue":"19","key":"1211_CR23","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.vaccine.2018.03.058","volume":"36","author":"HF Gidding","year":"2018","unstructured":"Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, et al. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia. Vaccine. 2018;36(19):2650\u20136.","journal-title":"Vaccine"},{"issue":"23","key":"1211_CR24","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.vaccine.2015.04.005","volume":"33","author":"G Deceuninck","year":"2015","unstructured":"Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684\u20139.","journal-title":"Vaccine"},{"issue":"9","key":"1211_CR25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jpids\/piac038","volume":"11","author":"A Kabir","year":"2022","unstructured":"Kabir A, Newall AT, Randall D, Moore HC, Jayasinghe S, Fathima P, et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in medically at-risk children in Australia: a record linkage study. J Pediatr Infect Dis Soc. 2022;11(9):391\u20139.","journal-title":"J Pediatr Infect Dis Soc"},{"issue":"3","key":"1211_CR26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/ciy129","volume":"67","author":"S Jayasinghe","year":"2018","unstructured":"Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-year observational study. Clin Infect Dis. 2018;67(3):367\u201374.","journal-title":"Clin Infect Dis"},{"issue":"9546","key":"1211_CR27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","volume":"368","author":"CG Whitney","year":"2006","unstructured":"Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case\u2013control study. Lancet. 2006;368(9546):1495\u2013502.","journal-title":"Lancet"},{"issue":"6","key":"1211_CR28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/INF.0b013e3181cffa2a","volume":"29","author":"G Deceuninck","year":"2010","unstructured":"Deceuninck G, De Wals P, Boulianne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29(6):546\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"40","key":"1211_CR29","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1016\/j.vaccine.2021.08.068","volume":"39","author":"AH Baqui","year":"2021","unstructured":"Baqui AH, Koffi AK, McCollum ED, Roy AD, Chowdhury NH, Rafiqullah I, et al. Impact of national introduction of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Bangladesh: case\u2013control and time-trend studies. Vaccine. 2021;39(40):5794\u2013801.","journal-title":"Vaccine"},{"issue":"6","key":"1211_CR30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-2600(14)70060-8","volume":"2","author":"CMAS Domingues","year":"2014","unstructured":"Domingues CMAS, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case\u2013control study. Lancet Respir Med. 2014;2(6):464\u201371.","journal-title":"Lancet Respir Med"},{"key":"1211_CR31","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijid.2018.12.007","volume":"80","author":"A Riaz","year":"2019","unstructured":"Riaz A, Mohiuddin S, Husain S, Yousafzai MT, Sajid M, Kabir F, et al. Effectiveness of 10-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in Pakistan. Int J Infect Dis. 2019;80:28\u201333.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"1211_CR32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.vaccine.2023.12.007","volume":"42","author":"R Malaker","year":"2024","unstructured":"Malaker R, Hasanuzzaman M, Hooda Y, Rahman H, Chandra Das R, Kanon N, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: a prospective population-based study in rural Bangladesh. Vaccine. 2024;42(2):255\u201362.","journal-title":"Vaccine"},{"issue":"38","key":"1211_CR33","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1016\/j.vaccine.2023.07.049","volume":"41","author":"G Deceuninck","year":"2023","unstructured":"Deceuninck G, Brousseau N, Lefebvre B, Quach C, Tapiero B, Bui Y-G, et al. Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada. Vaccine. 2023;41(38):5486\u20139.","journal-title":"Vaccine"},{"issue":"7","key":"1211_CR34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/erv.11.76","volume":"10","author":"MC Nunes","year":"2011","unstructured":"Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vacc. 2011;10(7):951\u201380.","journal-title":"Expert Rev Vacc"},{"issue":"9","key":"1211_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135270","volume":"10","author":"K Bonner","year":"2015","unstructured":"Bonner K, Welch E, Elder K, Cohn J. Impact of pneumococcal conjugate vaccine administration in pediatric older age groups in low and middle-income countries: a systematic review. PLoS ONE. 2015;10(9): e0135270.","journal-title":"PLoS ONE"},{"issue":"13","key":"1211_CR36","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1017\/S095026881700125X","volume":"145","author":"BM Althouse","year":"2017","unstructured":"Althouse BM, Hammitt LL, Grant L, Wagner BG, Reid R, Larzelere-Hinton F, et al. Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities. Epidemiol Infect. 2017;145(13):2750\u20138.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"1211_CR37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1186\/s12887-024-05003-7","volume":"24","author":"J Weaver","year":"2024","unstructured":"Weaver J, Hu T, Podmore B, Barnett R, Oberm\u00fcller D, Galetzka W, et al. Incidence of pneumococcal disease in children in Germany, 2014\u20132019: a retrospective cohort study. BMC Pediatr. 2024;24(1):755.","journal-title":"BMC Pediatr"},{"issue":"5","key":"1211_CR38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(23)00706-5","volume":"24","author":"M Bertran","year":"2024","unstructured":"Bertran M, D\u2019Aeth JC, Abdullahi F, Eletu S, Andrews NJ, Ramsay ME, et al. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Lancet Infect Dis. 2024;24(5):546\u201356.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"1211_CR39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2352-4642(24)00211-6","volume":"8","author":"C Levy","year":"2024","unstructured":"Levy C, Cohen R. Pneumococcal conjugate vaccine schedule: 3+ 1, 2+ 1, or 1+ 1? Lancet Child Adolesc Health. 2024;8(11):774\u20135.","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"1211_CR40","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/cid\/ciy1127","volume":"69","author":"C-Y Lu","year":"2019","unstructured":"Lu C-Y, Chiang C-S, Chiu C-H, Wang E-T, Chen Y-Y, Yao S-M, et al. Successful control of Streptococcus pneumoniae 19A replacement with a catch-up primary vaccination program in Taiwan. Clin Infect Dis. 2019;69(9):1581\u20137.","journal-title":"Clin Infect Dis"},{"issue":"45","key":"1211_CR41","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1016\/j.vaccine.2019.09.038","volume":"37","author":"K van Zandvoort","year":"2019","unstructured":"van Zandvoort K, Checchi F, Diggle E, Eggo RM, Gadroen K, Mulholland K, et al. Pneumococcal conjugate vaccine use during humanitarian crises. Vaccine. 2019;37(45):6787\u201392.","journal-title":"Vaccine"},{"issue":"1","key":"1211_CR42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/INF.0000000000000484","volume":"34","author":"C von Mollendorf","year":"2015","unstructured":"von Mollendorf C, Cohen C, de Gouveia L, Naidoo N, Meiring S, Quan V, et al. Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012. Pediatr Infect Dis J. 2015;34(1):27\u201334.","journal-title":"Pediatr Infect Dis J"},{"issue":"27","key":"1211_CR43","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1016\/j.vaccine.2012.04.017","volume":"30","author":"G De Serres","year":"2012","unstructured":"De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine. 2012;30(27):4067\u201372.","journal-title":"Vaccine"},{"issue":"14","key":"1211_CR44","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.vaccine.2005.12.025","volume":"24","author":"BE Mahon","year":"2006","unstructured":"Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO Jr, Pelton SI, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24(14):2514\u201320.","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"1211_CR45","doi-asserted-by":"crossref","first-page":"C109","DOI":"10.1016\/j.vaccine.2013.01.059","volume":"31","author":"T Picon","year":"2013","unstructured":"Picon T, Alonso L, Garcia Gabarrot G, Speranza N, Casas M, Arrieta F, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data. Vaccine. 2013;31(Suppl 3):C109\u201313.","journal-title":"Vaccine"},{"issue":"31","key":"1211_CR46","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1016\/j.vaccine.2010.05.021","volume":"28","author":"S Ruckinger","year":"2010","unstructured":"Ruckinger S, van der Linden M, Reinert RR, von Kries R. Efficacy of 7-valent pneumococcal conjugate vaccination in Germany: an analysis using the indirect cohort method. Vaccine. 2010;28(31):5012\u20136.","journal-title":"Vaccine"},{"issue":"9","key":"1211_CR47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","volume":"14","author":"NJ Andrews","year":"2014","unstructured":"Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839\u201346.","journal-title":"Lancet Infect Dis"},{"issue":"49","key":"1211_CR48","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.vaccine.2011.09.112","volume":"29","author":"E Miller","year":"2011","unstructured":"Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127\u201331.","journal-title":"Vaccine"},{"issue":"5","key":"1211_CR49","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2213-2600(16)00052-7","volume":"4","author":"MR Moore","year":"2016","unstructured":"Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case\u2013control study. Lancet Respir Med. 2016;4(5):399\u2013406.","journal-title":"Lancet Respir Med"},{"issue":"18","key":"1211_CR50","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.vaccine.2016.02.043","volume":"34","author":"R Weinberger","year":"2016","unstructured":"Weinberger R, van der Linden M, Imohl M, von Kries R. Vaccine effectiveness of PCV13 in a 3+1 vaccination schedule. Vaccine. 2016;34(18):2062\u20135.","journal-title":"Vaccine"},{"issue":"19","key":"1211_CR51","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.vaccine.2022.03.048","volume":"40","author":"LJ Ricketson","year":"2022","unstructured":"Ricketson LJ, Bettinger JA, Sadarangani M, Halperin SA, Kellner JD, Canadian Immunization Monitoring Program AI. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: an IMPACT study. Vaccine. 2022;40(19):2733\u201340.","journal-title":"Vaccine"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01211-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01211-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:12Z","timestamp":1759138032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01211-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01211-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eileen M. Dunne, Benjamin M. Althouse, Kyla Hayford, Luis Jodar, Bradford D. Gessner, and Christian Theilacker are current or former employees of Pfizer and may own Pfizer stock or stock options. Linge Hong is a former employee of Pfizer (paid internship).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}